Physician profile
Julia Le
NPI 1437833829
$2,180.64
in general payments reported to CMS, 2019-2025
20 companies · $891 in 2025
The $891 reported for 2025 was more than what 81% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $191 · 2024: $1,099 · 2025: $891.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,181.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,180.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $464.91 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $325.29 | 2023-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $264.06 | 2024-2025 | Airsupra, Farxiga, Breztri |
| Amgen INC. | $219.39 | 2024-2025 | Repatha, Otezla, Krystexxa |
| Novo Nordisk INC | $188.43 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Inspire Medical Systems, INC. | $155.40 | 2024-2025 | Inspire |
| Glaxosmithkline, LLC. | $134.69 | 2024-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Exact Sciences Corporation | $122.49 | 2023-2025 | Cologuard Collection Kit |
| Dexcom, INC. | $79.49 | 2024-2025 | Dexcom G6 Transmitter |
| Hologic Sales and Service, LLC | $41.54 | 2025 | Aptima |
| Pfizer INC. | $38.65 | 2024 | |
| Ibsa Pharma INC. | $22.45 | 2024 | Licart, Tirosint |
| Astellas Pharma US INC | $17.33 | 2025 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $17.27 | 2024 | |
| Csl Behring | $16.48 | 2024 | Haegarda |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $15.88 | 2024 | Voquezna |
| Abbvie INC. | $14.65 | 2025 | |
| Xeris Pharmaceuticals, INC. | $14.46 | 2023 | Keveyis |
| Azurity Pharmaceuticals, INC. | $14.15 | 2024 | |
| Janssen Pharmaceuticals, INC | $13.63 | 2025 | Spravato |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julia Le listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.